G1 Therapeutics, Inc.
GTHX · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $157,787 | $236,890 | $428,242 | $681,426 |
| - Cash | $32,281 | $94,594 | $221,186 | $207,306 |
| + Debt | $57,173 | $83,765 | $83,055 | $27,758 |
| Enterprise Value | $182,679 | $226,061 | $290,111 | $501,878 |
| Revenue | $82,511 | $51,301 | $31,476 | $45,285 |
| % Growth | 60.8% | 63% | -30.5% | – |
| Gross Profit | $75,316 | $47,553 | $29,460 | $45,285 |
| % Margin | 91.3% | 92.7% | 93.6% | 100% |
| EBITDA | -$34,301 | -$134,897 | -$142,457 | -$95,484 |
| % Margin | -41.6% | -263% | -452.6% | -210.9% |
| Net Income | -$47,967 | -$147,559 | -$148,352 | -$99,254 |
| % Margin | -58.1% | -287.6% | -471.3% | -219.2% |
| EPS Diluted | -0.93 | -3.38 | -3.54 | -2.62 |
| % Growth | 72.5% | 4.5% | -35.1% | – |
| Operating Cash Flow | -$38,337 | -$128,620 | -$132,108 | -$83,742 |
| Capital Expenditures | $0 | -$506 | $0 | $0 |
| Free Cash Flow | -$38,337 | -$129,126 | -$132,108 | -$83,742 |